BM30 peptide

BM30 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

XPKR-NH2, X is 4-hydroxyphenylacetyl

4

96.2%

C₂₅H₄₀N₈O₅

532.64

Synthetic

Powder

BM30 is the first potent peptidomimetic inhibitor for N-terminal methyltransferase1/2 (NTMT1/2). BM30 has a half-maximal inhibitory concentration of 0.89 ± 0.10 μM, is a competitive inhibitor to the peptide substrate and is noncompetitive to the cofactor S-adenosylmethionine. BM30 exhibits over 100-fold selectivity for NTMT1/2 among a panel of 41 methyl transferases, showing great potential for high selectivity when targeting the peptide substrate binding site of NTMT1/2. Its cell-permeable analogue DC432 is also available, which can decrease the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Mackie et al (2020) Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies. J Med Chem. 63(17) 9512 PMID: 32689795

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.